55 related articles for article (PubMed ID: 38452155)
1. Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy.
Bracco C; Gallarate M; Badinella Martini M; Magnino C; D'Agnano S; Canta R; Racca G; Melchio R; Serraino C; Polla Mattiot V; Gollè G; Fenoglio L
World J Gastrointest Oncol; 2024 Mar; 16(3):761-772. PubMed ID: 38577451
[TBL] [Abstract][Full Text] [Related]
2. Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades.
Kaneko S; Asahina Y; Murakawa M; Azuma S; Inada K; Mochida T; Watakabe K; Shimizu T; Tsuchiya J; Miyoshi M; Kawai-Kitahata F; Nitta S; Takahashi M; Fujioka T; Kishino M; Anzai T; Kakinuma S; Nakagawa M; Okamoto R
PLoS One; 2024; 19(3):e0297882. PubMed ID: 38452155
[TBL] [Abstract][Full Text] [Related]
3. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
4. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade.
Ho SY; Yuan MH; Liu PH; Hsu CY; Huang YH; Liao JI; Su CW; Wang CL; Hou MC; Huo TI
Scand J Gastroenterol; 2023 Jan; 58(1):61-69. PubMed ID: 35830511
[TBL] [Abstract][Full Text] [Related]
5. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.
Gómez-Rodríguez R; Romero-Gutiérrez M; Artaza-Varasa T; González-Frutos C; Ciampi-Dopazo JJ; de-la-Cruz-Pérez G; Sánchez-Ruano JJ
Rev Esp Enferm Dig; 2012 Jun; 104(6):298-304. PubMed ID: 22738699
[TBL] [Abstract][Full Text] [Related]
6. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
7. Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection.
Li C; Zhang XY; Peng W; Wen TF; Yan LN; Li B; Yang JY; Wang WT; Xu MQ; Chen LP
Medicine (Baltimore); 2018 Jul; 97(29):e11599. PubMed ID: 30024565
[TBL] [Abstract][Full Text] [Related]
8. Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
Nakagawa M; Asahina Y; Kakinuma S; Okamoto R
J Gastroenterol; 2023 Apr; 58(4):299-310. PubMed ID: 36585501
[TBL] [Abstract][Full Text] [Related]
9. Annual report to the nation on the status of cancer: This latest report, a collaboration from the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries, shows that cancer mortality rates have accelerated, and incidence rates remain stable, with pancreatic cancer showing an increase in both incidence and mortality: This latest report, a collaboration from the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries, shows that cancer mortality rates have accelerated, and incidence rates remain stable, with pancreatic cancer showing an increase in both incidence and mortality.
Nierengarten MB
Cancer; 2023 Jan; 129(1):8. PubMed ID: 36507862
[No Abstract] [Full Text] [Related]
10. Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shimose S; Hiraoka A; Tanaka M; Iwamoto H; Tanaka T; Noguchi K; Aino H; Yamaguchi T; Itano S; Suga H; Niizeki T; Moriyama E; Shirono T; Noda Y; Kamachi N; Okamura S; Nakano M; Kawaguchi T; Kuromatsu R; Koga H; Torimura T
Sci Rep; 2022 Oct; 12(1):17018. PubMed ID: 36220865
[TBL] [Abstract][Full Text] [Related]
11. Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.
Kaneko S; Tsuchiya K; Yasui Y; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Hayakawa Y; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Takahashi Y; Nakanishi H; Irie T; Ariizumi SI; Kurosaki M; Izumi N
JGH Open; 2022 May; 6(5):301-308. PubMed ID: 35601130
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Sekiguchi S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Kurosaki M; Izumi N
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1613. PubMed ID: 35302279
[TBL] [Abstract][Full Text] [Related]
13. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kobayashi K; Ogasawara S; Takahashi A; Seko Y; Unozawa H; Sato R; Watanabe S; Moriguchi M; Morimoto N; Tsuchiya S; Iwai K; Inoue M; Ogawa K; Ishino T; Iwanaga T; Sakuma T; Fujita N; Kanzaki H; Koroki K; Nakamura M; Kanogawa N; Kiyono S; Kondo T; Saito T; Nakagawa R; Suzuki E; Ooka Y; Nakamoto S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Nagashima K; Kato J; Isoda N; Aramaki T; Itoh Y; Kato N
Liver Cancer; 2022 Jan; 11(1):48-60. PubMed ID: 35222507
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
